The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.
Mario Boccadoro
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Federica Cavallo
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Francesca Maria Gay
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Francesco Di Raimondo
Honoraria - Celgene
Arnon Nagler
No relevant relationships to disclose
Vittorio Montefusco
No relevant relationships to disclose
Francesca Patriarca
Honoraria - Celgene
Paola Tacchetti
No relevant relationships to disclose
Tommasina Guglielmelli
No relevant relationships to disclose
Pellegrino Musto
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Luca Baldini
Honoraria - Celgene
Claudia Crippa
No relevant relationships to disclose
Marina Ruggeri
No relevant relationships to disclose
Fabiana Gentilini
No relevant relationships to disclose
Maide Cavalli
No relevant relationships to disclose
Dina Ben Yehuda
No relevant relationships to disclose
Tommaso Caravita
No relevant relationships to disclose
Giovannino Ciccone
No relevant relationships to disclose
Izhar Hardan
No relevant relationships to disclose
Antonio Palumbo
Consultant or Advisory Role - Celgene
Honoraria - Celgene